BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update: Treatment of latent TB infection. Respirology 2010;15:603-22. [DOI: 10.1111/j.1440-1843.2010.01751.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol 2022. [PMID: 35478222 DOI: 10.1038/s41579-022-00731-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
2 Lauar ID, Faria LC, Romanelli RMC, Clemente WT. Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area. World J Transplant 2021; 11(12): 512-522 [DOI: 10.5500/wjt.v11.i12.512] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Yang H, Park H. Factors influencing the initiation and adherence of LTBI treatment in healthcare workers: a systematic review. Arch Environ Occup Health 2021;:1-11. [PMID: 34184972 DOI: 10.1080/19338244.2021.1943642] [Reference Citation Analysis]
4 Shin A, Lee YJ, Lee EB, Song YW, Kim SC, Kang EH. Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. Rheumatology (Oxford) 2021;60:2755-64. [PMID: 33188421 DOI: 10.1093/rheumatology/keaa702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Grijota-Camino MD, Montero N, Luque MJ, Díaz-Jurado M, Sabé N, Pérez-Recio S, Couceiro C, Muñoz L, Cruzado JM, Santin M. Tuberculosis prevention in patients undergoing kidney transplantation: A nurse-led program for screening and treatment. Transpl Infect Dis 2021;:e13603. [PMID: 33745229 DOI: 10.1111/tid.13603] [Reference Citation Analysis]
6 Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, Motahar M, Moradi M, Bazyar H. Bedaquiline: Current status and future perspectives. J Glob Antimicrob Resist 2021;25:48-59. [PMID: 33684606 DOI: 10.1016/j.jgar.2021.02.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
7 Escalante P, Arias-guillén M, Palacios Gutiérrez JJ. New research strategies in latent tuberculosis infection. Archivos de Bronconeumología (English Edition) 2021;57:151-153. [DOI: 10.1016/j.arbr.2020.01.011] [Reference Citation Analysis]
8 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
9 Shen Y, Ma H, Luo D, Cai J, Zou J, Bao Z, Guan J. Behçet's disease with latent Mycobacterium tuberculosis infection. Open Med (Wars) 2021;16:14-22. [PMID: 33336078 DOI: 10.1515/med-2021-0002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Stockbridge EL, Loethen AD, Annan E, Miller TL. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. PLoS One 2020;15:e0243102. [PMID: 33270737 DOI: 10.1371/journal.pone.0243102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Liu Y, Phares CR, Posey DL, Maloney SA, Cain KP, Weinberg MS, Schmit KM, Marano N, Cetron MS. Tuberculosis among Newly Arrived Immigrants and Refugees in the United States. Ann Am Thorac Soc 2020;17:1401-12. [PMID: 32730094 DOI: 10.1513/AnnalsATS.201908-623OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Fox GJ, Dodd PJ, Marais BJ. Household contact investigation to improve tuberculosis control. Lancet Infect Dis 2019;19:235-7. [PMID: 30833052 DOI: 10.1016/S1473-3099(19)30061-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Escalante P, Arias-Guillén M, Palacios Gutiérrez JJ. New Research Strategies in Latent Tuberculosis Infection. Arch Bronconeumol (Engl Ed) 2021;57:151-3. [PMID: 32192764 DOI: 10.1016/j.arbres.2020.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Almeida Santos J, Duarte R, Nunes C. Tuberculin skin test and predictive host factors for false-negative results in patients with pulmonary and extrapulmonary tuberculosis. Clin Respir J 2020;14:541-8. [PMID: 32052551 DOI: 10.1111/crj.13166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Thomas K, Hadziyannis E, Hatzara C, Makris A, Tsalapaki C, Lazarini A, Klavdianou K, Antonatou K, Koutsianas C, Vassilopoulos D. Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathog Immun 2020;5:34-51. [PMID: 32258853 DOI: 10.20411/pai.v5i1.349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Saha S, Kumar A, Saurabh K, Shankar SH, Kashyap A, Nischal N, Biswas A, Wig N. Current status of treatment of latent tuberculosis infection in India. IJMS 2020;71:54-9. [DOI: 10.25259/ijms_18_2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Leong S, Zhao Y, Ribeiro-Rodrigues R, Jones-López EC, Acuña-Villaorduña C, Rodrigues PM, Palaci M, Alland D, Dietze R, Ellner JJ, Johnson WE, Salgame P. Cross-validation of existing signatures and derivation of a novel 29-gene transcriptomic signature predictive of progression to TB in a Brazilian cohort of household contacts of pulmonary TB. Tuberculosis (Edinb) 2020;120:101898. [PMID: 32090859 DOI: 10.1016/j.tube.2020.101898] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
18 Fox GJ, Nguyen CB, Nguyen TA, Tran PT, Marais BJ, Graham SM, Nguyen BH, Velen K, Dowdy DW, Mason P, Britton WJ, Behr MA, Benedetti A, Menzies D, Nguyen VN, Marks GB. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open 2020;10:e033945. [PMID: 31900274 DOI: 10.1136/bmjopen-2019-033945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
19 Huppertz H, Nadal D. Atypische bakterielle Infektionen: Mykobakteriosen. Pädiatrie 2020. [DOI: 10.1007/978-3-662-60300-0_362] [Reference Citation Analysis]
20 Nguyen B, Fox GJ, Mason PH, Denholm JT. Preventive Therapy for Multidrug Resistant Latent Tuberculosis Infection: An Ethical Imperative with Ethical Barriers to Implementation? Ethics and Drug Resistance: Collective Responsibility for Global Public Health 2020. [DOI: 10.1007/978-3-030-27874-8_2] [Reference Citation Analysis]
21 Castellana G, Castellana M, Castellana C, Castellana G, Resta E, Carone M, Resta O. Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies. Int J Chron Obstruct Pulmon Dis 2019;14:2219-27. [PMID: 31576118 DOI: 10.2147/COPD.S209273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
22 Wyndham-Thomas C, Dirix V, Goffard JC, Henrard S, Wanlin M, Callens S, Mascart F, Van Vooren JP. 2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients. Acta Clin Belg 2019;74:242-51. [PMID: 30036162 DOI: 10.1080/17843286.2018.1494669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Аksenovа VА, Klevno NI, Kаzаkov АV, Gordinа АV, Fаtykhovа RK; National Medical Research Center of Phthisiopulmonology and Infectious Diseases, National Medical Research Center of Phthisiopulmonology and Infectious Diseases, National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Central Research Institute for Public Health Organization and Informatization, Republican Clinical TB Dispensary, Kazan, Tatarstan Republic. PREVENTIVE CHEMOTHERAPY IN CHILDREN EXPOSED TO MULTIPLE DRUG RESISTANT TUBERCULOSIS. TIBL 2019;97:36-43. [DOI: 10.21292/2075-1230-2019-97-6-36-43] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Huppertz H, Nadal D. Atypische bakterielle Infektionen bei Kindern und Jugendlichen: Mykobakteriosen. Pädiatrie 2019. [DOI: 10.1007/978-3-642-54671-6_362-1] [Reference Citation Analysis]
25 Dale KD, Trauer JM, Dodd PJ, Houben R, Denholm JT. Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia. Eur Respir J 2018;52:1801218. [DOI: 10.1183/13993003.01218-2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
26 Thakur R, Krishnaswamy Sashindran V. Latent Tuberculosis Infection: Patho-Biology and Treatment. Advances in HIV and AIDS Control 2018. [DOI: 10.5772/intechopen.76665] [Reference Citation Analysis]
27 Lambert LA, Katz D, Feng PJ, Djojonegoro BM, Fair E, Jasuja S, Marantz S, Horsburgh CR Jr, Ho C. Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and Completion. Microbiol Insights 2018;11:1178636118811311. [PMID: 30505150 DOI: 10.1177/1178636118811311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Scolarici M, Dekitani K, Chen L, Sokol-Anderson M, Hoft DF, Chatterjee S. A scoring strategy for progression risk and rates of treatment completion in subjects with latent tuberculosis. PLoS One 2018;13:e0207582. [PMID: 30440033 DOI: 10.1371/journal.pone.0207582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health 2018;3:e001135. [PMID: 30364389 DOI: 10.1136/bmjgh-2018-001135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
30 Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis 2018;24:2272-7. [PMID: 29718223 DOI: 10.1093/ibd/izy133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kang J, Jeong DH, Yoo B, Lee CK, Kim YG, Hong S, Shim TS, Jo KW. The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea. Respir Med 2018;143:109-15. [PMID: 30261981 DOI: 10.1016/j.rmed.2018.09.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Hovell MF, Schmitz KE, Blumberg EJ, Hill L, Sipan C, Friedman L. Lessons learned from two interventions designed to increase adherence to LTBI treatment in Latino youth. Contemp Clin Trials Commun 2018;12:129-36. [PMID: 30456327 DOI: 10.1016/j.conctc.2018.08.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Huang H, Yuan G, Du Y, Cai X, Liu J, Hu C, Liang B, Hu G, Tang X, Zhou Y. Effects of preventive therapy for latent tuberculosis infection and factors associated with treatment abandonment: a cross-sectional study. J Thorac Dis 2018;10:4377-86. [PMID: 30174886 DOI: 10.21037/jtd.2018.06.138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology 2018;23:893-900. [PMID: 29901251 DOI: 10.1111/resp.13346] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
35 Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther 2018;16:501-12. [PMID: 29848120 DOI: 10.1080/14787210.2018.1483238] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
36 Friedman EE, Dean HD, Duffus WA. Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Public Health Rep 2018;133:392-412. [PMID: 29874147 DOI: 10.1177/0033354918774788] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
37 Baddley J, Cantini F, Goletti D, Gómez-reino J, Mylonakis E, San-juan R, Fernández-ruiz M, Torre-cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clinical Microbiology and Infection 2018;24:S10-20. [DOI: 10.1016/j.cmi.2017.12.025] [Cited by in Crossref: 100] [Cited by in F6Publishing: 111] [Article Influence: 20.0] [Reference Citation Analysis]
38 Guix-Comellas EM, Rozas-Quesada L, Velasco-Arnaiz E, Ferrés-Canals A, Estrada-Masllorens JM, Force-Sanmartín E, Noguera-Julian A. Impact of nursing interventions on adherence to treatment with antituberculosis drugs in children and young people: A nonrandomized controlled trial. J Adv Nurs 2018. [PMID: 29726024 DOI: 10.1111/jan.13692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
39 Бабушкина Н, Брагина Е, Гараева А, Гончарова И, Цитриков Д, Гомбоева Д, Рудко А, Фрейдин М. Identification of genetic predisposition to latent tuberculosis infection. Nauchno-prakticheskii zhurnal «Medicinskaia genetika» 2018. [DOI: 10.25557/2073-7998.2018.01.27-31] [Reference Citation Analysis]
40 Kelly S, Noone P, Reid A. Screening for latent tuberculosis in UK health care workers. Occupational Medicine 2018;68:72-72. [DOI: 10.1093/occmed/kqx181] [Reference Citation Analysis]
41 Liu Y, Birch S, Newbold KB, Essue BM. Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature. Int J Health Plann Mgmt 2017;33:e416-33. [DOI: 10.1002/hpm.2495] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
42 Jagger A, Reiter-Karam S, Hamada Y, Getahun H. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ 2018;96:173-184F. [PMID: 29531416 DOI: 10.2471/BLT.17.199414] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
43 Lam CK, Mcginnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study (Preprint).. [DOI: 10.2196/preprints.9825] [Reference Citation Analysis]
44 Li J, Yip BHK, Leung C, Chung W, Kwok KO, Chan EYY, Yeoh E, Chung P. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area. PLoS One 2018;13:e0189531. [PMID: 29293514 DOI: 10.1371/journal.pone.0189531] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
45 Scolarici M, Dekitani K, Chen L, Sokol-anderson M, Hoft DF, Chatterjee S. Use of a scoring strategy to determine clinical risk of progression and risk group-specific treatment adherence in subjects with latent tuberculosis infection.. [DOI: 10.1101/207852] [Reference Citation Analysis]
46 Danyuttapolchai J, Kittimunkong S, Nateniyom S, Painujit S, Klinbuayaem V, Maipanich N, Maokamnerd Y, Pevzner E, Whitehead S, Kanphukiew A, Monkongdee P, Martin M. Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. PLoS One 2017;12:e0184986. [PMID: 28949995 DOI: 10.1371/journal.pone.0184986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tang P, Johnston J. Treatment of Latent Tuberculosis Infection. Curr Treat Options Infect Dis 2017;9:371-9. [PMID: 29238270 DOI: 10.1007/s40506-017-0135-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
48 Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. Role of the Health Department in Tuberculosis Prevention and Control-Legal and Public Health Considerations. Microbiol Spectr 2017;5. [PMID: 28256190 DOI: 10.1128/microbiolspec.TNMI7-0034-2016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
49 Lim CH, Chen HH, Chen YH, Chen DY, Huang WN, Tsai JJ, Hsieh TY, Hsieh CW, Hung WT, Lin CT, Lai KL, Tang KT, Tseng CW, Chen YM. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan. PLoS One 2017;12:e0178035. [PMID: 28570568 DOI: 10.1371/journal.pone.0178035] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
50 LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis 2017;17:e327-33. [PMID: 28495525 DOI: 10.1016/S1473-3099(17)30248-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
51 Reddy D, Walker J, White LF, Brandeis GH, Russell ML, Horsburgh CR Jr, Hochberg NS. Latent Tuberculosis Infection Testing Practices in Long-Term Care Facilities, Boston, Massachusetts. J Am Geriatr Soc 2017;65:1145-51. [PMID: 28467605 DOI: 10.1111/jgs.14696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
52 Lee J, Kim E, Jang EJ, Lee C, Lee EY, Im JP, Han SK, Yim J. Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist. Annals ATS 2017;14:690-7. [DOI: 10.1513/annalsats.201608-647oc] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
53 Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. Role of the Health Department in Tuberculosis Prevention and Control-Legal and Public Health Considerations. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch15] [Reference Citation Analysis]
54 Haley CA. Treatment of Latent Tuberculosis Infection. Tuberculosis and Nontuberculous Mycobacterial Infections 2017. [DOI: 10.1128/9781555819866.ch6] [Reference Citation Analysis]
55 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
56 Kiazyk S, Ball TB. Latent tuberculosis infection: An overview. Can Commun Dis Rep 2017;43:62-6. [PMID: 29770066 DOI: 10.14745/ccdr.v43i34a01] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 8.5] [Reference Citation Analysis]
57 Pease C, Amaratunga KR, Alvarez GG. A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians. Can Commun Dis Rep 2017;43:67-71. [PMID: 29770067 DOI: 10.14745/ccdr.v43i34a02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
58 Huang YW, Yang SF, Yeh YP, Tsao TC, Tsao SM. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Medicine (Baltimore) 2016;95:e4126. [PMID: 27559940 DOI: 10.1097/MD.0000000000004126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
59 Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B, Martinez JA, Kromann I, Penas A, Anibarro LL, de Souza-Galvão ML, Sánchez F, Rodrigo-Pendás JÁ, Noguera-Julian A, Martínez-Lacasa X, Tuñez MV, Fernández VL, Millet JP, Moreno A, Cobos N, Miró JM, Roldan L, Orcau A, Andersen P, Caylá JA; TESEC Working Group. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med 2017;5:259-68. [PMID: 28159608 DOI: 10.1016/S2213-2600(16)30436-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 9.2] [Reference Citation Analysis]
60 Zhou L, Liu E. Preventive Therapy Against Tuberculosis. Handbook of Global Tuberculosis Control 2017. [DOI: 10.1007/978-1-4939-6667-7_23] [Reference Citation Analysis]
61 Min DH, Wy HH, Shim JW, Kim DS, Jung HL, Park MS, Shim JY. Risk factors for latent tuberculosis in children who had close contact to households with pulmonary tuberculosis. Allergy Asthma Respir Dis 2017;5:105. [DOI: 10.4168/aard.2017.5.2.105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 No DJ, Darji K, Amin M, Wu JJ. Tuberculosis Infection in a 58-Year-Old with Psoriasis. Clinical Cases in Psoriasis 2017. [DOI: 10.1007/978-3-319-52779-6_18] [Reference Citation Analysis]
63 Jo KW. Preventing the Transmission of Tuberculosis in Health Care Settings: Administrative Control. Tuberc Respir Dis (Seoul) 2017;80:21-6. [PMID: 28119743 DOI: 10.4046/trd.2017.80.1.21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
64 Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis 2017;64:e1-e33. [PMID: 27932390 DOI: 10.1093/cid/ciw694] [Cited by in Crossref: 241] [Cited by in F6Publishing: 260] [Article Influence: 34.4] [Reference Citation Analysis]
65 Turetz ML, Ma KC. Diagnosis and management of latent tuberculosis. Curr Opin Infect Dis 2016;29:205-11. [PMID: 26836374 DOI: 10.1097/QCO.0000000000000253] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
66 Kowada A. Cost-effectiveness of interferon-gamma release assays for tuberculosis screening in nursing homes. Epidemiol Infect 2016;144:3215-25. [PMID: 27412626 DOI: 10.1017/S0950268816001382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
67 Gao L, Bai L, Liu J, Lu W, Wang X, Li X, Du J, Chen X, Zhang H, Xin H, Sui H, Li H, Su H, He J, Pan S, Peng H, Xu Z, Catanzaro A, Evans TG, Zhang Z, Ma Y, Li M, Feng B, Li Z, Guan L, Shen F, Wang Z, Zhu T, Yang S, Si H, Wang Y, Tan Y, Chen T, Chen C, Xia Y, Cheng S, Xu W, Jin Q; LATENTTB-NSTM study team. Annual risk of tuberculosis infection in rural China: a population-based prospective study. Eur Respir J 2016;48:168-78. [PMID: 27230438 DOI: 10.1183/13993003.00235-2016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
68 van Zyl-Smit RN, van Hest R. The Intention to Test for Latent Tuberculosis Should Be a Targeted Intention to Trust and Treat the Result. Ann Am Thorac Soc 2016;13:591-2. [PMID: 27144789 DOI: 10.1513/AnnalsATS.201511-734ED] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 van Lier A, McDonald SA, Bouwknegt M, Kretzschmar ME, Havelaar AH, Mangen MJ, Wallinga J, de Melker HE; EPI group. Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011. PLoS One 2016;11:e0153106. [PMID: 27097024 DOI: 10.1371/journal.pone.0153106] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
70 Liao TL, Lin CH, Chen YM, Chang CL, Chen HH, Chen DY. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan. PLoS One 2016;11:e0153217. [PMID: 27064275 DOI: 10.1371/journal.pone.0153217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
71 Rockwood N, du Bruyn E, Morris T, Wilkinson RJ. Assessment of treatment response in tuberculosis. Expert Rev Respir Med 2016;10:643-54. [PMID: 27030924 DOI: 10.1586/17476348.2016.1166960] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
72 Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF, Medina J, Medina Y, Jaimes D, Arbelaez AM, Domínguez AM, Fernández A, Felipe-díaz OJ, Chalem P, Caballero Uribe CV, Jannaut MJ, García I, Bautista W, Ramírez Figueroa J, Cortés J, Quintero J, Rodríguez N. Gestión de riesgo para la prescripción de terapias biológicas. Revista Colombiana de Reumatología 2016;23:50-67. [DOI: 10.1016/j.rcreu.2016.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF, Medina J, Medina Y, Jaimes D, Arbelaez AM, Domínguez AM, Fernández A, Felipe-díaz OJ, Chalem P, Caballero Uribe CV, Jannaut MJ, García I, Bautista W, Ramírez Figueroa J, Cortés J, Quintero J, Rodríguez N. Risk management for prescribing biological therapies. Revista Colombiana de Reumatología (English Edition) 2016;23:50-67. [DOI: 10.1016/j.rcreue.2016.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Wilson SR, Halley M, Knowles S. Health Disparities as They Relate to Medication Adherence. Health Disparities in Respiratory Medicine 2016. [DOI: 10.1007/978-3-319-23675-9_6] [Reference Citation Analysis]
75 Young KH, Ehman M, Reves R, Maddox BLP, Khan A, Chorba TL, Jereb J. Tuberculosis Contact Investigations — United States, 2003–2012. MMWR Morb Mortal Wkly Rep 2016;64:1369-74. [DOI: 10.15585/mmwr.mm6450a1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
76 Escalante P, Peikert T, Van Keulen VP, Erskine CL, Bornhorst CL, Andrist BR, McCoy K, Pease LR, Abraham RS, Knutson KL, Kita H, Schrum AG, Limper AH. Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification. Am J Respir Crit Care Med 2015;192:605-17. [PMID: 26030344 DOI: 10.1164/rccm.201412-2141OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
77 Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563-76. [PMID: 26405286 DOI: 10.1183/13993003.01245-2015] [Cited by in Crossref: 353] [Cited by in F6Publishing: 375] [Article Influence: 44.1] [Reference Citation Analysis]
78 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014;9:169-294. [PMID: 25404581 DOI: 10.1002/ebch.1962] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
79 Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, Goletti D. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews 2015;14:503-9. [DOI: 10.1016/j.autrev.2015.01.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 13.9] [Reference Citation Analysis]
80 Shivaramakrishna HR, Frederick A, Shazia A, Murali L, Satyanarayana S, Nair SA, Kumar AM, Moonan PK. Isoniazid preventive treatment in children in two districts of South India: does practice follow policy? Int J Tuberc Lung Dis 2014;18:919-24. [PMID: 25199005 DOI: 10.5588/ijtld.14.0072] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
81 Liu Y, Posey DL, Cetron MS, Painter JA. Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Ann Intern Med 2015;162:420-8. [PMID: 25775314 DOI: 10.7326/M14-2082] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
82 Loebinger MR, Pozniak A. Screening for latent tuberculosis before tumour necrosis factor antagonist therapy. Eur Respir J 2015;45:1512-1513. [DOI: 10.1183/09031936.00020315] [Reference Citation Analysis]
83 Lee SH. Diagnosis and treatment of latent tuberculosis infection. Tuberc Respir Dis (Seoul) 2015;78:56-63. [PMID: 25861337 DOI: 10.4046/trd.2015.78.2.56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
84 Guix-Comellas EM, Rozas-Quesada L, Force-Sanmartín E, Estrada-Masllorens JM, Galimany-Masclans J, Noguera-Julian A. Influence of nursing interventions on adherence to treatment with antituberculosis drugs in children and young people: research protocol. J Adv Nurs 2015;71:2189-99. [PMID: 25818512 DOI: 10.1111/jan.12656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
85 Castro AT, Mendes M, Freitas S, Roxo PC. Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years. Rev Port Pneumol (2006) 2015;21:144-50. [PMID: 25926250 DOI: 10.1016/j.rppnen.2014.08.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
86 Hufnagel M, Schmitt H, Nadal D, Christen H, Eiffert H, Huppertz H. Bakterielle Infektionen bei Kindern und Jugendlichen: Atypische Bakterien. Pädiatrie 2015. [DOI: 10.1007/978-3-642-54671-6_122-1] [Reference Citation Analysis]
87 Lin SY, Chen TC, Lu PL, Lin CY, Lin WR, Yang YH, Chen YH. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infect Dis 2014;14:705. [PMID: 25523602 DOI: 10.1186/s12879-014-0705-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
88 Cakar B, Demir N, Karnak D, Ozkara S. Tuberculosis preventive treatment in a single medical center and evaluation of the results. Exp Ther Med 2014;8:1874-8. [PMID: 25371747 DOI: 10.3892/etm.2014.1988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Lim YP, Lin CL, Hung DZ, Lin YN, Kao CH. Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study. Eur J Clin Microbiol Infect Dis. 2015;34:479-485. [PMID: 25260789 DOI: 10.1007/s10096-014-2251-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
90 Hazlewood GS, Naimark D, Gardam M, Bykerk V, Bombardier C. Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. Arthritis Care Res (Hoboken) 2013;65:1722-31. [PMID: 23836530 DOI: 10.1002/acr.22063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
91 Cansu DÜ, Güncan S, Bilge NŞ, Kaşifoğlu T, Korkmaz C. Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-α agent with a disease-modifying antirheumatic drug? Eur J Rheumatol 2014;1:62-6. [PMID: 27708877 DOI: 10.5152/eurjrheumatol.2014.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology 2014;53:1872-85. [DOI: 10.1093/rheumatology/keu172] [Cited by in Crossref: 102] [Cited by in F6Publishing: 108] [Article Influence: 11.3] [Reference Citation Analysis]
93 Kwon M, Sung M, Kwon Y, Song YG, Lee S, Park M, Park Y, Lee S, Song JJ. Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis: . JCR Journal of Clinical Rheumatology 2014;20:68-73. [DOI: 10.1097/rhu.0000000000000074] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
94 Krátký M, Vinšová J, Novotná E, Stolaříková J. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase. European Journal of Pharmaceutical Sciences 2014;53:1-9. [DOI: 10.1016/j.ejps.2013.12.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
95 Hufnagel M, Schmitt H, Nadal D, Christen H, Eiffert H, Huppertz H. Bakterielle Infektionen: Atypische Bakterien. Pädiatrie 2014. [DOI: 10.1007/978-3-642-41866-2_99] [Reference Citation Analysis]
96 Fox GJ, Marks GB, Britton WJ. Current transmission prevention methods: reducing disease spread from infected individuals. Clinical Insights: Tuberculosis Prevention 2014. [DOI: 10.2217/ebo.13.507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Bozarth AL, Salkind AR. Tuberculosis. Hospital Medicine Clinics 2014;3:e50-e70. [DOI: 10.1016/j.ehmc.2013.07.003] [Reference Citation Analysis]
98 Gallardo CR, Gea Velázquez de Castro MT, Requena Puche J, Miralles Bueno JJ, Rigo Medrano MV, Aranaz Andrés JM. [Factors associated with treatment adherence for tuberculosis infection]. Aten Primaria 2014;46:6-14. [PMID: 24331920 DOI: 10.1016/j.aprim.2013.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
99 . Missed opportunities for prevention of tuberculosis in children. Annals of Tropical Paediatrics 2013;31:297-9. [DOI: 10.1179/146532811x13142348016691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
100 Coleman MS, Marienau KJ, Marano N, Marks SM, Cetron MS. Economics of United States tuberculosis airline contact investigation policies: a return on investment analysis. Travel Med Infect Dis 2014;12:63-71. [PMID: 24262643 DOI: 10.1016/j.tmaid.2013.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
101 Salina E, Ryabova O, Kaprelyants A, Makarov V. New 2-thiopyridines as potential candidates for killing both actively growing and dormant Mycobacterium tuberculosis cells. Antimicrob Agents Chemother 2014;58:55-60. [PMID: 24126578 DOI: 10.1128/AAC.01308-13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
102 Sanz-bueno J, Castellanos-gonzález M, Fernández-ruiz M, Lizasoain M, Rivera R. Pautas alternativas en el tratamiento de la infección tuberculosa latente en el paciente con psoriasis. Piel 2013;28:448-450. [DOI: 10.1016/j.piel.2013.02.011] [Reference Citation Analysis]
103 Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;:CD007545. [PMID: 23828580 DOI: 10.1002/14651858.CD007545.pub2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
104 Mulder C, Mulleners B, Borgdorff MW, van Leth F. Predictive value of the tuberculin skin test among newly arriving immigrants. PLoS One 2013;8:e60130. [PMID: 23544128 DOI: 10.1371/journal.pone.0060130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
105 Chen SC, Chen KL, Chen KH, Chien ST, Chen KT. Updated diagnosis and treatment of childhood tuberculosis. World J Pediatr 2013;9:9-16. [PMID: 23389330 DOI: 10.1007/s12519-013-0404-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
106 Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, Xu S, Rahman MU. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res 2013;65:309-13. [DOI: 10.1002/acr.21788] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
107 Chee CB, Sester M, Zhang W, Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis: LTBI diagnosis and treatment. Respirology 2013;18:205-16. [DOI: 10.1111/resp.12002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
108 Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest. 2012;142:761-773. [PMID: 22948580 DOI: 10.1378/chest.12-0142] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
109 Weant TE, Turner AN, Murphy-Weiss M, Murray DM, Wang SH. Can social history variables predict prison inmates' risk for latent tuberculosis infection? Tuberc Res Treat 2012;2012:132406. [PMID: 23320160 DOI: 10.1155/2012/132406] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
110 Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 2013;207:1242-52. [PMID: 22891286 DOI: 10.1093/infdis/jis425] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
111 Goswami ND, Gadkowski LB, Piedrahita C, Bissette D, Ahearn MA, Blain ML, Østbye T, Saukkonen J, Stout JE. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health 2012;12:468. [PMID: 22720842 DOI: 10.1186/1471-2458-12-468] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
112 Oliveira SM, Ruffino-Netto A, Paniago AM, Oliveira OA, Marques M, Cunha RV, Andreotti R. Tuberculin skin test: operational research in the state of Mato Grosso do Sul, Brazil. J Bras Pneumol 2011;37:646-54. [PMID: 22042397 DOI: 10.1590/s1806-37132011000500012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
113 Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012;186:273-9. [PMID: 22561962 DOI: 10.1164/rccm.201111-2076OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
114 Lee J, Gong S, Lee B, Lee S, Lee J, Kim N. Miliary tuberculosis occurred after immunosuppressive drug in PNH patient with completely cured tuberculosis; a case report. Ann Clin Microbiol Antimicrob 2012;11:12. [PMID: 22554314 DOI: 10.1186/1476-0711-11-12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Marquez L, Starke JR. Diagnosis and management of TB in children: an update. Expert Rev Anti Infect Ther 2011;9:1157-68. [PMID: 22114966 DOI: 10.1586/eri.11.144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
116 Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R. Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012;205 Suppl 2:S228-40. [PMID: 22476720 DOI: 10.1093/infdis/jir858] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 10.4] [Reference Citation Analysis]
117 Fraisse P. Traitement des infections tuberculeuses latentes. Revue des Maladies Respiratoires 2012;29:579-600. [DOI: 10.1016/j.rmr.2011.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
118 Abubakar I, Stagg HR, Cohen T, Mangtani P, Rodrigues LC, Pimpin L, Watson JM, Squire SB, Zumla A. Controversies and unresolved issues in tuberculosis prevention and control: a low-burden-country perspective. J Infect Dis 2012;205 Suppl 2:S293-300. [PMID: 22448025 DOI: 10.1093/infdis/jir886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
119 Kang SJ, Kim YH, Jung CY, Lee HJ, Hyun MC. Clinical Characteristics and Radiologic Patterns of Adelescents with Pulmonary Tuberculosis: Relevance to the Reactive Tuberculosis. Pediatr Allergy Respir Dis 2012;22:163. [DOI: 10.7581/pard.2012.22.2.163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 Benjumea D. Tratamiento para la infección latente por tuberculosis en niños: recomendaciones internacionales y para Colombia. Infectio 2012;16:173-7. [DOI: 10.1016/s0123-9392(12)70008-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Miyata T, Cheigh CI, Casali N, Goodridge A, Marjanovic O, Kendall LV, Riley LW. An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis. Vaccine 2012;30:459-65. [PMID: 22079078 DOI: 10.1016/j.vaccine.2011.10.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
122 Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res 2011;50:202-12. [PMID: 21717066 DOI: 10.1007/s12026-011-8229-7] [Cited by in Crossref: 116] [Cited by in F6Publishing: 123] [Article Influence: 9.7] [Reference Citation Analysis]
123 Jamrozik E, Musk AW. Respiratory health issues in the Asia-Pacific region: an overview. Respirology 2011;16:3-12. [PMID: 20920119 DOI: 10.1111/j.1440-1843.2010.01844.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
124 Lee SH, Yim JJ, Kim HJ, Shim TS, Seo HS, Cho YS, Lee HK, Lee YM, Lee EJ, Lew WJ. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect 2012;140:1028-35. [PMID: 21835069 DOI: 10.1017/S0950268811001476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
125 Leung CC, Feller-kopman D, Niederman MS, Spiro SG. Year in review 2010: Tuberculosis, pleural diseases, respiratory infections. Respirology 2011;16:564-573. [DOI: 10.1111/j.1440-1843.2011.01940.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
126 Kubo S, Yamaoka K, Saito K, Tanaka Y. Péricardite induite par l’administration prophylactique d’isoniazide chez un patient atteint de polyarthrite rhumatoïde. Revue du Rhumatisme 2011;78:191-192. [DOI: 10.1016/j.rhum.2010.10.003] [Reference Citation Analysis]
127 Peña JM. Aclaraciones al documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. Enfermedades Infecciosas y Microbiología Clínica 2011;29:162-3. [DOI: 10.1016/j.eimc.2010.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
128 Shleeva MO, Kudykina YK, Vostroknutova GN, Suzina NE, Mulyukin AL, Kaprelyants AS. Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Tuberculosis (Edinb) 2011;91:146-54. [PMID: 21262587 DOI: 10.1016/j.tube.2010.12.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
129 Kubo S, Yamaoka K, Saito K, Tanaka Y. Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. Joint Bone Spine 2011;78:99-100. [DOI: 10.1016/j.jbspin.2010.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
130 Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, O’grady J, Bates M, Dheda K, Hoelscher M, Grange J. Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection: Latent M. tuberculosis infection. Tropical Medicine & International Health 2011;16:79-83. [DOI: 10.1111/j.1365-3156.2010.02665.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
131 Yew WW, Cynamon M, Zhang Y. Emerging drugs for the treatment of tuberculosis. Expert Opin Emerg Drugs 2011;16:1-21. [PMID: 20868293 DOI: 10.1517/14728214.2011.521497] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
132 Kelly PM. Commentary on ‘Reminder Systems and Late Patient Tracers in the Diagnosis and Management of Tuberculosis’. Evid -Based Child Health 2010;5:1248-1250. [DOI: 10.1002/ebch.575] [Reference Citation Analysis]